Glovax is the First and Only company that brought in the AH1N1 Swine Flu Pandemic Vaccine in 2009/10.

Glovax makes
affordable and accessible!

About Us

Giovanni Alingog is the Founder and Chief Executive Officer (CEO) of Glovax Biotech Corp.

Man on a Mission

Entrepreneur of the year sold wedding gifts to provide affordable vaccines for the poor.

Forty one-year-old Giovanni Alingog is a visionary. If he isn’t one, what kind of a man would persuade his wife to sell their wedding gifts, and with its earnings, venture on vaccine distribution. The year was 2003.

Forward to 2015, Alingog has successfully put up Glovax Biotech Corporation, a company that spearheads the country’s efforts to become self-reliant against deadly diseases, especially during pandemics such as the dreaded SARS, AH1N1, Swine Flu, and even Ebola, by discovering and developing new vaccines.

From the P80,000 seed capital, Glovax now enjoys the support of Impact Investment Asia (IIX) and Kohlberg Kravis Roberts (KRR), a leading global private equity firm with over $400 Billion in equity transactions.

“It was not difficult to convince my wife,” recalls Alingog of his company’s humble beginnings. Alingog who is incidentally married to a pediatrician adds, “What we actually did was find a solution to her problem which was to source out affordable vaccines for the less privileged.”


An accountancy graduate of the San Beda College and a Certified Public Accountant (CPA), Alingog first went into the logistics business of freight forwarding and brokerage before he realized that there is something bigger that he and his wife could do to serve the country and the people better.

To date, Glovax, through the assistance of Rotary International, Philippine Institute of Certified Public Accountants (PICPA) of which he is a member, local government units, and non-government organizations, have vaccinated a total of 133,000 underprivileged individuals for free. The vaccines provided by Glovax, such as the ones for meningococcemia, pneumonia, and influenza are not given by the government since these are costly.

“The vaccination program has benefitted residents to as far as Patikul, Sulu; poverty-stricken areas in Quezon Province and Daet, Camarines Norte and impoverished communities in Metro Manila such as in Quezon City, Manila, Mandaluyong, and Pasay City,” he proudly says.

Alingog’s humanitarian efforts were recently recognized by PICPA through its “Entrepreneurship of the Year” award. Prior to the recognition, he was also PICPA’s special awardee for community service in 2011.


Glovax will put up a R2 Billion vaccine and biotech research and development plant at no cost to the government that will provide the much needed technology transfer to the Government of the Philippines (GOP) in order to build its capacity in producing its own vaccines and be self-reliant.

The company also proposed a plan called Vaccine Development and Security Program (VDSP), a long-term project which aims to help the government in its annual vaccine requirement by making sure that the vaccines are available anytime and at pre-determined prices.

“Because the technology to produce the vaccines is now available locally, Glovax has improved our ability to provide universal health care. We do not need to be dependent on outside suppliers for vaccines,” Alingog concludes.

- Manila Bulletin, February 24, 2015

Read more about Mr. Alingog:

Malaya News - February 25, 2015

Malaya News - February 25, 2015

Social Impact Assessment